Literature DB >> 31197067

Efficiency of blinatumomab in a t(8;21) acute myeloid leukemia expressing CD19.

Adriana Plesa1, Hélène Labussière-Wallet2, Sandrine Hayette1, Gilles Salles2,3, Xavier Thomas2, Pierre Sujobert4,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31197067      PMCID： PMC6886432          DOI： 10.3324/haematol.2019.225557

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  4 in total

1.  Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.

Authors:  Hagop Kantarjian; Anthony Stein; Nicola Gökbuget; Adele K Fielding; Andre C Schuh; Josep-Maria Ribera; Andrew Wei; Hervé Dombret; Robin Foà; Renato Bassan; Önder Arslan; Miguel A Sanz; Julie Bergeron; Fatih Demirkan; Ewa Lech-Maranda; Alessandro Rambaldi; Xavier Thomas; Heinz-August Horst; Monika Brüggemann; Wolfram Klapper; Brent L Wood; Alex Fleishman; Dirk Nagorsen; Christopher Holland; Zachary Zimmerman; Max S Topp
Journal:  N Engl J Med       Date:  2017-03-02       Impact factor: 91.245

2.  Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34.

Authors:  K Kita; K Nakase; H Miwa; M Masuya; K Nishii; N Morita; N Takakura; A Otsuji; S Shirakawa; T Ueda
Journal:  Blood       Date:  1992-07-15       Impact factor: 22.113

3.  Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup.

Authors:  Marie-Anne Hospital; Thomas Prebet; Sarah Bertoli; Xavier Thomas; Emmanuelle Tavernier; Thorsten Braun; Cécile Pautas; Aurore Perrot; Bruno Lioure; Philippe Rousselot; Jérôme Tamburini; Thomas Cluzeau; Johanna Konopacki; Edouard Randriamalala; Céline Berthon; Marie-Pierre Gourin; Christian Recher; Jean-Yves Cahn; Norbert Ifrah; Hervé Dombret; Nicolas Boissel
Journal:  Blood       Date:  2014-07-08       Impact factor: 22.113

4.  Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.

Authors:  Monique Terwijn; Wendelien Zeijlemaker; Angèle Kelder; Arjo P Rutten; Alexander N Snel; Willemijn J Scholten; Thomas Pabst; Gregor Verhoef; Bob Löwenberg; Sonja Zweegman; Gert J Ossenkoppele; Gerrit J Schuurhuis
Journal:  PLoS One       Date:  2014-09-22       Impact factor: 3.240
  4 in total
  1 in total

1.  RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses.

Authors:  Matti Kankainen; Satu Mustjoki; Shady Adnan Awad; Olli Dufva; Aleksandr Ianevski; Bishwa Ghimire; Jan Koski; Pilvi Maliniemi; Daniel Thomson; Andreas Schreiber; Caroline A Heckman; Perttu Koskenvesa; Matti Korhonen; Kimmo Porkka; Susan Branford; Tero Aittokallio
Journal:  Leukemia       Date:  2020-08-11       Impact factor: 11.528
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.